During the corresponding time, Aligos Therapeutics Inc recorded a revenue increase by 809.97 % year on year, sequentially revenue grew by 1574.56 %. While revenue at the Aligos Therapeutics Inc 's corporate clients
Aligos Therapeutics Sets Stage for EASL Congress 2025 with Eight Accepted s SOUTH SAN FRANCISCO, Calif. April 23, 2025 Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical-stage biopharmaceutical company dedicated to enhancing patient outcomes through advanced therapies targeting liver and viral diseases, today announced that eight of its research abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2025. The event is scheduled to take place from May 7 to May 10, 2025, in Amsterdam, Netherlands.The accepted abstracts highlight Aligos’s commitment to addressing pressing challenges in liver and viral disease management. Specific detail...
Aligos Therapeutics Reveals Positive Phase 2a HERALD Study Findings for ALG-055009 in MASH Treatment SOUTH SAN FRANCISCO, Calif. Sept. 19, 2024 Aligos Therapeutics, Inc. (Nasdaq: ALGS), a pioneering clinical stage biopharmaceutical firm dedicated to advancing therapeutic outcomes for liver and viral diseases, has announced encouraging topline results from its Phase 2a HERALD study investigating ALG-055009, a novel thyroid hormone receptor beta (THR-β) agonist. The study focuses on patients diagnosed with metabolic-dysfunction associated steatohepatitis, commonly referred to as MASH, a condition exacerbated by increasing rates of obesity and metabolic syndrome in contemporary populations.MASH represents ...
Aligos Therapeutics, a renowned clinical-stage biopharmaceutical company, has recently made significant progress in developing innovative therapeutics to combat chronic hepatitis B (CHB) and metabolic dysfunction-associated steatohepatitis (MASH). This article will outline the key findings from their KOL event, the passing of an influential industry leader, and the initiation of their Phase 2a HERALD study, and assess their impact on the company s future endeavors. 1. Positive Phase 1b Data for ALG-000184 in CHB Treatment:Aligos Therapeutics is thrilled to announce the successful outcome of the Phase 1b study for ALG-000184, a potential breakthrough treatment for chronic hepatitis B (CHB). The company hosted...
The pharmaceutical industry recently mourned the loss of Dr. Stephen A. Harrison, a renowned industry leader in metabolic dysfunction-associated steatohepatitis (MASH) research. With his profound expertise and guidance, Dr. Harrison played a pivotal role as a trusted advisor and Principal Investigator for the ongoing Phase 2a HERALD study conducted by Aligos Therapeutics, Inc. This somber news leaves a void in the field, as his contributions to liver and viral diseases research were invaluable. In this article, we remember and honor the lasting impact of Dr. Harrison s career.Background:Aligos Therapeutics, a clinical stage biopharmaceutical company specializing in novel therapies for liver and viral disease...
Sources:
Aligos Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Aligos Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Aligos Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
